BCRX stock news

BCRX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

16 wire items

2026-10-21 15:04:06 UTC#494005newconfirmednews

BioCryst Pharmaceuticals receives FDA approval for Orladeyo oral pellets

seeking alphaimportance 0.50trust 0.80BioCryst Pharmaceuticals, Inc. +0.60Orladeyo +0.60U.S. Food and Drug Administration +0.20

2026-10-05 11:00:00 UTC#412846newconfirmedpress release

BioCryst Pharmaceuticals forms new Scientific Advisory Board to guide rare disease R&D strategy

globenewswireimportance 0.30trust 0.90BioCryst Pharmaceuticals, Inc. +0.20Sandeep Menon +0.10

2026-09-30 18:04:00 UTC#393579newconfirmednews

JPMorgan Maintains Neutral Rating on BioCryst Pharmaceuticals (BCRX)

dow_jonesimportance 0.30trust 0.70BioCryst Pharmaceuticals, Inc. 0JPMorgan Chase & Co. 0

2026-09-15 15:08:08 UTC#314881newconfirmednews

BioCryst Pharmaceuticals (BCRX) outlines strategic shift toward external innovation and profitability

quartrimportance 0.30trust 0.50BioCryst Pharmaceuticals, Inc. +0.40Orladeyo +0.40Navenibart +0.40

2026-09-10 14:46:00 UTC#293102newconfirmednews

RBC Capital downgrades BioCryst Pharmaceuticals to Sector Perform from Outperform, cuts PT to $11 from $13

dow_jonesimportance 0.40trust 0.70BioCryst Pharmaceuticals, Inc. -0.50RBC Capital Markets, LLC -0.50

2026-09-08 17:42:00 UTC#282618newconfirmednews

Needham maintains $16.00 price target on BioCryst Pharmaceuticals (BCRX)

dow_jonesimportance 0.30trust 0.70BioCryst Pharmaceuticals, Inc. 0Needham & Company, LLC 0

2026-08-28 11:00:01 UTC#234693newconfirmednews

BioCryst Pharmaceuticals shifts to acquisition strategy for rare disease assets after reaching profitability

cnbcimportance 0.40trust 0.80BioCryst Pharmaceuticals, Inc. +0.40

2026-08-25 11:38:37 UTC#217105newconfirmedpress release

BioCryst Pharmaceuticals receives Japanese regulatory approval for Orladeyo in pediatric HAE patients

reutersimportance 0.40trust 0.90BioCryst Pharmaceuticals, Inc. +0.60Orladeyo +0.60Japan +0.40

2026-08-06 17:18:00 UTC#139126newconfirmednews

RBC Capital cuts BioCryst Pharmaceuticals (BCRX) price target to $13 from $14, maintains Outperform

dow_jonesimportance 0.30trust 0.70BioCryst Pharmaceuticals, Inc. -0.30RBC Capital Markets, LLC -0.30

2026-08-06 11:31:34 UTC#136815newconfirmedpress release

BioCryst Pharmaceuticals, Inc. (BCRX) releases 2026 Q2 earnings call presentation

seeking alphaimportance 0.30trust 0.90BioCryst Pharmaceuticals, Inc. 0

2026-08-05 16:03:01 UTC#131201updateconfirmednews

BioCryst Pharmaceuticals issues 2026 revenue guidance of $690M-$715M and operating costs of $420M-$440M

seeking alphaimportance 0.50trust 0.70BioCryst Pharmaceuticals, Inc. +0.40

2026-08-05 13:31:59 UTC#130256duplicateconfirmednews

BioCryst Pharmaceuticals Q2 adjusted EPS $0.30 beats $0.12 estimate, revenue $218.25M beats $182.51M

reutersimportance 0.30trust 0.90BioCryst Pharmaceuticals, Inc. +0.80

2026-08-05 12:18:02 UTC#129740updateconfirmednews

BioCryst Pharmaceuticals reports $354M in cash and equivalents as of June 30, 2026

reutersimportance 0.30trust 0.90BioCryst Pharmaceuticals, Inc. +0.20

2026-08-05 11:10:48 UTC#129253newconfirmednews

BioCryst Pharmaceuticals beats Q2 earnings and revenue estimates, updates FY26 outlook

seeking alphaimportance 0.40trust 0.70BioCryst Pharmaceuticals, Inc. +0.50

2026-07-07 15:46:00 UTC#8123newconfirmednews

RBC Capital Maintains Outperform Rating on BioCryst Pharmaceuticals

dow_jonesimportance 0.30trust 0.80BioCryst Pharmaceuticals, Inc. +0.20RBC Capital Markets, LLC +0.20

2026-07-06 11:19:44 UTC#2241newconfirmednews

BioCryst Clears Orladeyo Pellet Delay, Cuts 2026 Expense Outlook

tradingviewimportance 0.40trust 0.70BioCryst Pharmaceuticals, Inc. +0.60Orladeyo +0.50Cantor Fitzgerald, L.P. +0.40+2 entities